Literature DB >> 20962019

Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?

Ashraf H Ahmed1, Richard D Gordon, Paul J Taylor, Gregory Ward, Eduardo Pimenta, Michael Stowasser.   

Abstract

BACKGROUND: Because primary aldosteronism is not uncommon, specifically treatable and in some cases curable, and carries higher risks for cardiovascular morbidity and mortality than essential hypertension, screening hypertensive patients for its presence by measuring aldosterone to renin ratio (ARR) is increasingly common. A significantly higher false-positive ARR rate for women than men, resulting in unnecessary suppression tests has previously been reported.
METHODS: Using a new, highly accurate aldosterone assay and both of the currently widely used renin assays, ARR was measured in 19 normal, ovulating women at three time points in the menstrual cycle and compared with single measurements in 21 normal males of similar age.
RESULTS: ARRs in males were possibly too well down in the current normal range. Although normotensive and normokalemic, two women had raised ARRs in the luteal phase but only when direct renin concentration (DRC) was used. Their DRC levels were low at all sampling times [despite midrange plasma renin activity levels], whereas their progesterone and aldosterone levels were highest for the group. Saline suppression testing, performed in one of them, showed normal aldosterone suppressibility.
CONCLUSION: False-positive ARRs in normal women during the luteal phase only when DRC is used may explain the higher incidence of false-positive ARRs in hypertensive women than men and suggest the following: 1) plasma renin activity is preferable to DRC in determination of ARR and 2) new reference ranges for ARR that take into account gender and sex hormone levels are required.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962019     DOI: 10.1210/jc.2010-1355

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Potential effects of age on screening for primary aldosteronism.

Authors:  Q Luo; N F Li; X G Yao; D L Zhang; S F Y Abulikemu; G J Chang; K M Zhou; G L Wang; M H Wang; W J Ouyang; Q Y Cheng; Y Jia
Journal:  J Hum Hypertens       Date:  2015-04-16       Impact factor: 3.012

Review 2.  The use of mass spectrometry to improve the diagnosis and the management of the HPA axis.

Authors:  Phillip J Monaghan; Brian G Keevil; Peter J Trainer
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

Review 3.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 4.  Aldosterone excess and resistant hypertension: investigation and treatment.

Authors:  Michael Stowasser
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

Review 5.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

6.  Postmenopausal osteoporosis is associated with elevated aldosterone/renin ratio.

Authors:  Xiaoyu Shu; Mei Mei; Linqiang Ma; Zhihong Wang; Shumin Yang; Jinbo Hu; Ying Song; Wenwen He; Ting Luo; Qingfeng Cheng; Yue Wang; Qianna Zhen; Qifu Li
Journal:  J Hum Hypertens       Date:  2018-05-22       Impact factor: 3.012

7.  Metabolomics and incident hypertension among blacks: the atherosclerosis risk in communities study.

Authors:  Yan Zheng; Bing Yu; Danny Alexander; Thomas H Mosley; Gerardo Heiss; Jennifer A Nettleton; Eric Boerwinkle
Journal:  Hypertension       Date:  2013-06-17       Impact factor: 10.190

Review 8.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

Review 9.  Immunohistochemistry of the adrenal in primary aldosteronism.

Authors:  Celso E Gomez-Sanchez; Elise P Gomez-Sanchez
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-06       Impact factor: 3.243

10.  NT-proBNP, a useful tool in hypertensive patients undergoing a diagnostic evaluation for primary aldosteronism.

Authors:  Francesca Pizzolo; Francesco Zorzi; Laura Chiecchi; Letizia Consoli; Irene Aprili; Patrizia Guarini; Annalisa Castagna; Gian Luca Salvagno; Chiara Pavan; Oliviero Olivieri
Journal:  Endocrine       Date:  2013-08-13       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.